# Matthew J. Weiss

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/matthew-j-weiss/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,120 |
| Field | Pancreatic and Hepatic Oncology Research |
| h-index | 74 |
| i10-index | 271 |
| Last Known Institution | Northwell Health |
| OpenAlex ID | https://openalex.org/A5014748431 |
| ORCID iD | 0000-0003-0553-248X |
| Works | 573 |

## Researcher papers

- [Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma](https://scholariq.org/papers/patterns-timing-and-predictors-of-recurrence-following-pancreatectomy-for/)
- [Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers](https://scholariq.org/papers/combined-circulating-tumor-dna-and-protein-biomarker-based-liquid-biopsy-for-the/)
- [Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma](https://scholariq.org/papers/multi-institutional-validation-study-of-the-american-joint-commission-on-cancer/)
- [Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma](https://scholariq.org/papers/deleterious-germline-mutations-in-patients-with-apparently-sporadic-pancreatic/)
- [A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts](https://scholariq.org/papers/a-combination-of-molecular-markers-and-clinical-features-improve-the/)
- [Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance](https://scholariq.org/papers/risk-of-neoplastic-progression-in-individuals-at-high-risk-for-pancreatic-cancer/)
- [Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection](https://scholariq.org/papers/survival-in-locally-advanced-pancreatic-cancer-after-neoadjuvant-therapy-and/)
- [Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma](https://scholariq.org/papers/defining-and-predicting-early-recurrence-in-957-patients-with-resected/)
- [Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity](https://scholariq.org/papers/neoadjuvant-cabozantinib-and-nivolumab-convert-locally-advanced-hepatocellular/)
- [Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis](https://scholariq.org/papers/neoadjuvant-folfirinox-in-patients-with-borderline-resectable-pancreatic-cancer/)
- [Early <i>versus</i> late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent](https://scholariq.org/papers/early-i-versus-i-late-recurrence-of-intrahepatic-cholangiocarcinoma-after/)
- [Surgeon Re-Excision Rates after Breast-Conserving Surgery: A Measure of Low-Value Care](https://scholariq.org/papers/surgeon-re-excision-rates-after-breast-conserving-surgery-a-measure-of-low-value/)

## Researcher topics

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Northwell Health](https://scholariq.org/institutions/northwell-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.